Currently, there is no FDA-approved therapeutics available for NAFLD, although several classes of drugs for NAFLD/NASH treatment are under development, (i.e., FXR agonists and PPAR agonists) [31]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.